A citation-based method for searching scientific literature

Hope S Rugo, Adam M Brufsky, Marianne Ulcickas Yood, Debu Tripathy, Peter A Kaufman, Musa Mayer, Bongin Yoo, Oyewale O Abidoye, Denise A Yardley. Breast Cancer Res Treat 2013
Times Cited: 27







List of co-cited articles
131 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
29

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
José Baselga, Javier Cortés, Sung-Bae Kim, Seock-Ah Im, Roberto Hegg, Young-Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pienkowski, Adam Knott,[...]. N Engl J Med 2012
25

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
Shaheenah Dawood, Kristine Broglio, Aman U Buzdar, Gabriel N Hortobagyi, Sharon H Giordano. J Clin Oncol 2010
520
22

Characteristics associated with differences in survival among black and white women with breast cancer.
Jeffrey H Silber, Paul R Rosenbaum, Amy S Clark, Bruce J Giantonio, Richard N Ross, Yun Teng, Min Wang, Bijan A Niknam, Justin M Ludwig, Wei Wang,[...]. JAMA 2013
199
22

Disparities in breast cancer characteristics and outcomes by race/ethnicity.
Siew Loon Ooi, Maria Elena Martinez, Christopher I Li. Breast Cancer Res Treat 2011
198
18

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
18


Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
Javaid Iqbal, Ophira Ginsburg, Paula A Rochon, Ping Sun, Steven A Narod. JAMA 2015
343
18

Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population.
Kaitlin B Baron, Jennifer R Brown, Brian L Heiss, Joanne Marshall, Nancy Tait, Katherine H R Tkaczuk, Stephen S Gottlieb. J Card Fail 2014
19
26

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.
Peter A Kaufman, Adam M Brufsky, Musa Mayer, Hope S Rugo, Debu Tripathy, Marianne Ulcickas Yood, Shibao Feng, Lisa I Wang, Cheng S Quah, Denise A Yardley. Breast Cancer Res Treat 2012
41
14

Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Erica T Warner, Rulla M Tamimi, Melissa E Hughes, Rebecca A Ottesen, Yu-Ning Wong, Stephen B Edge, Richard L Theriault, Douglas W Blayney, Joyce C Niland, Eric P Winer,[...]. J Clin Oncol 2015
158
14

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
Anya Litvak, Bhavina Batukbhai, Stuart D Russell, Hua-Ling Tsai, Gary L Rosner, Stacie C Jeter, Deborah Armstrong, Leisha A Emens, John Fetting, Antonio C Wolff,[...]. Cancer 2018
23
17

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Richard Bell, Christian Jackisch,[...]. N Engl J Med 2005
11

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, John Bryant, Vera J Suman, Charles E Geyer, Nancy E Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A Kaufman,[...]. N Engl J Med 2005
11

Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark Pegram, Do-Youn Oh, Véronique Diéras, Ellie Guardino,[...]. N Engl J Med 2012
11

Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, Miguel Martin, Michael Press, John Mackey, John Glaspy, Arlene Chan, Marek Pawlicki,[...]. N Engl J Med 2011
11

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Charles E Geyer, John Forster, Deborah Lindquist, Stephen Chan, C Gilles Romieu, Tadeusz Pienkowski, Agnieszka Jagiello-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman,[...]. N Engl J Med 2006
11

Prognostic factors in 1,038 women with metastatic breast cancer.
R Largillier, J-M Ferrero, J Doyen, J Barriere, M Namer, V Mari, A Courdi, J M Hannoun-Levi, F Ettore, I Birtwisle-Peyrottes,[...]. Ann Oncol 2008
238
11

Survival differences among women with de novo stage IV and relapsed breast cancer.
S Dawood, K Broglio, J Ensor, G N Hortobagyi, S H Giordano. Ann Oncol 2010
158
11

Breast cancer in African-American women.
Lisa A Newman. Oncologist 2005
124
11

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.
Shaheenah Dawood, Kristine Broglio, Ana M Gonzalez-Angulo, Aman U Buzdar, Gabriel N Hortobagyi, Sharon H Giordano. J Clin Oncol 2008
135
11

Fifteen-year trends in metastatic breast cancer survival in Greece.
U Dafni, I Grimani, A Xyrafas, A G Eleftheraki, G Fountzilas. Breast Cancer Res Treat 2010
58
11

Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Blase N Polite, Constance Cirrincione, Gini F Fleming, Donald A Berry, Andrew Seidman, Hyman Muss, Larry Norton, Charles Shapiro, Kamal Bakri, Kelly Marcom,[...]. J Clin Oncol 2008
25
12

Trastuzumab containing regimens for early breast cancer.
Lorenzo Moja, Ludovica Tagliabue, Sara Balduzzi, Elena Parmelli, Vanna Pistotti, Valentina Guarneri, Roberto D'Amico. Cochrane Database Syst Rev 2012
353
11

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Charles L Vogel, Melody A Cobleigh, Debu Tripathy, John C Gutheil, Lyndsay N Harris, Louis Fehrenbacher, Dennis J Slamon, Maureen Murphy, William F Novotny, Michael Burchmore,[...]. J Clin Oncol 2002
11

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Thomas M Suter, Marion Procter, Dirk J van Veldhuisen, Michael Muscholl, Jonas Bergh, Chiara Carlomagno, Timothy Perren, Rodolfo Passalacqua, Claudia Bighin, Jan G M Klijn,[...]. J Clin Oncol 2007
391
11

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Edith A Perez, Vera J Suman, Nancy E Davidson, George W Sledge, Peter A Kaufman, Clifford A Hudis, Silvana Martino, Julie R Gralow, Shaker R Dakhil, James N Ingle,[...]. J Clin Oncol 2008
386
11

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Erin J Aiello Bowles, Robert Wellman, Heather Spencer Feigelson, Adedayo A Onitilo, Andrew N Freedman, Thomas Delate, Larry A Allen, Larissa Nekhlyudov, Katrina A B Goddard, Robert L Davis,[...]. J Natl Cancer Inst 2012
337
11

Cancer statistics, 2016.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2016
11


Breast cancer statistics, 2015: Convergence of incidence rates between black and white women.
Carol E DeSantis, Stacey A Fedewa, Ann Goding Sauer, Joan L Kramer, Robert A Smith, Ahmedin Jemal. CA Cancer J Clin 2016
757
11

Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period.
Ayal A Aizer, Tyler J Wilhite, Ming-Hui Chen, Powell L Graham, Toni K Choueiri, Karen E Hoffman, Neil E Martin, Quoc-Dien Trinh, Jim C Hu, Paul L Nguyen. Cancer 2014
148
11

Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.
Tomi Akinyemiju, Justin Xavier Moore, Akinyemi I Ojesina, John W Waterbor, Sean F Altekruse. Breast Cancer Res Treat 2016
44
11

Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities.
Carol E DeSantis, Rebecca L Siegel, Ann Goding Sauer, Kimberly D Miller, Stacey A Fedewa, Kassandra I Alcaraz, Ahmedin Jemal. CA Cancer J Clin 2016
487
11

Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.
Katie M O'Brien, Stephen R Cole, Chiu-Kit Tse, Charles M Perou, Lisa A Carey, William D Foulkes, Lynn G Dressler, Joseph Geradts, Robert C Millikan. Clin Cancer Res 2010
270
11

Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.
Dawn L Hershman, Joseph M Unger, William E Barlow, Laura F Hutchins, Silvana Martino, C Kent Osborne, Robert B Livingston, Kathy S Albain. J Clin Oncol 2009
93
11

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
Geeta Gulati, Siri Lagethon Heck, Anne Hansen Ree, Pavel Hoffmann, Jeanette Schulz-Menger, Morten W Fagerland, Berit Gravdehaug, Florian von Knobelsdorff-Brenkenhoff, Åse Bratland, Tryggve H Storås,[...]. Eur Heart J 2016
323
11


Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study.
Li Tao, Scarlett Lin Gomez, Theresa H M Keegan, Allison W Kurian, Christina A Clarke. Cancer Epidemiol Biomarkers Prev 2015
70
11

Racial disparities in treatment and survival among women with early-stage breast cancer.
Dawn Hershman, Russell McBride, Judith S Jacobson, Lois Lamerato, Kevin Roberts, Victor R Grann, Alfred I Neugut. J Clin Oncol 2005
250
11

Comorbidity and survival disparities among black and white patients with breast cancer.
C Martin Tammemagi, David Nerenz, Christine Neslund-Dudas, Carolyn Feldkamp, David Nathanson. JAMA 2005
300
11

Metastatic behavior of breast cancer subtypes.
Hagen Kennecke, Rinat Yerushalmi, Ryan Woods, Maggie Chon U Cheang, David Voduc, Caroline H Speers, Torsten O Nielsen, Karen Gelmon. J Clin Oncol 2010
7

Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
Adedayo A Onitilo, Jessica M Engel, Robert T Greenlee, Bickol N Mukesh. Clin Med Res 2009
461
7

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
Erin M Olson, Julie S Najita, Jessica Sohl, Amal Arnaout, Harold J Burstein, Eric P Winer, Nancy U Lin. Breast 2013
78
7

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, Chad A Livasy, Lynn G Dressler, David Cowan, Kathleen Conway, Gamze Karaca, Melissa A Troester, Chiu Kit Tse, Sharon Edmiston,[...]. JAMA 2006
7


Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Joseph A Sparano, Molin Wang, Fengmin Zhao, Vered Stearns, Silvana Martino, Jennifer A Ligibel, Edith A Perez, Tom Saphner, Antonio C Wolff, George W Sledge,[...]. J Natl Cancer Inst 2012
66
7


Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Sara M Tolaney, William T Barry, Chau T Dang, Denise A Yardley, Beverly Moy, P Kelly Marcom, Kathy S Albain, Hope S Rugo, Matthew Ellis, Iuliana Shapira,[...]. N Engl J Med 2015
378
7

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Sharon H Giordano, Sarah Temin, Jeffrey J Kirshner, Sarat Chandarlapaty, Jennie R Crews, Nancy E Davidson, Francisco J Esteva, Ana M Gonzalez-Angulo, Ian Krop, Jennifer Levinson,[...]. J Clin Oncol 2014
243
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.